The global cerebral infarction treatment market size is expected to reach USD 20.5 billion by 2030 and is projected to grow at a CAGR of 7.3%. The growing prevalence of ischemic strokes, driven by an aging global population and increasing rates of lifestyle-related risk factors such as hypertension and diabetes, is a key factor in the expansion of the cerebral infarction treatment market.
According to a study published by the National Library of Medicine in March 2023, hemorrhagic stroke accounts for 10.0% to 20.0% of all strokes annually. The incidence varies significantly by region, with 8.0%-15.0% in the U.S., the UK, and Australia, and 18.0% to 24.0% in Japan and Korea. The rate of hemorrhagic stroke is notably higher in low- and middle-income countries, and among Asians. Furthermore, while stroke incidence is higher in men and increases with age, the global burden of hemorrhagic stroke is rising, particularly in African and Asian countries. Effective management of hypertension has been shown to reduce the incidence of intracerebral hemorrhage (ICH), though the fatality rate remains a concern, ranging from 25.0% to 30.0% in high-income countries and 30% to 48% in lower-income regions, highlighting disparities in critical care efficacy.
Technological advancements are significantly enhancing the treatment landscape for cerebral infarction. Innovations in thrombolytic therapies, such as tissue plasminogen activators (tPA), and development of mechanical thrombectomy devices have markedly improved patient outcomes. Moreover, the integration of artificial intelligence (AI) into diagnostic and treatment processes is revolutionizing stroke care. AI-driven algorithms now play a crucial role in predicting stroke risk and tailoring treatment strategies, which helps in personalizing care and improving overall efficacy. These advancements are not only improving the precision of treatments but also contributing to the broader adoption of advanced therapeutic options. Combined with increased investment in research and development, these technological strides are expected to drive significant growth in the cerebral infarction treatment market.
This product will be delivered within 2 business days.
According to a study published by the National Library of Medicine in March 2023, hemorrhagic stroke accounts for 10.0% to 20.0% of all strokes annually. The incidence varies significantly by region, with 8.0%-15.0% in the U.S., the UK, and Australia, and 18.0% to 24.0% in Japan and Korea. The rate of hemorrhagic stroke is notably higher in low- and middle-income countries, and among Asians. Furthermore, while stroke incidence is higher in men and increases with age, the global burden of hemorrhagic stroke is rising, particularly in African and Asian countries. Effective management of hypertension has been shown to reduce the incidence of intracerebral hemorrhage (ICH), though the fatality rate remains a concern, ranging from 25.0% to 30.0% in high-income countries and 30% to 48% in lower-income regions, highlighting disparities in critical care efficacy.
Technological advancements are significantly enhancing the treatment landscape for cerebral infarction. Innovations in thrombolytic therapies, such as tissue plasminogen activators (tPA), and development of mechanical thrombectomy devices have markedly improved patient outcomes. Moreover, the integration of artificial intelligence (AI) into diagnostic and treatment processes is revolutionizing stroke care. AI-driven algorithms now play a crucial role in predicting stroke risk and tailoring treatment strategies, which helps in personalizing care and improving overall efficacy. These advancements are not only improving the precision of treatments but also contributing to the broader adoption of advanced therapeutic options. Combined with increased investment in research and development, these technological strides are expected to drive significant growth in the cerebral infarction treatment market.
Cerebral Infarction Treatment Market Report Highlights
- In 2023, the ischemic stroke segment held the largest share of 78.6% due to its high prevalence, technological advancements, and growing awareness of early intervention
- The tissue plasminogen activators (tPA) segment secured the largest revenue share of 39.7% in 2023, driven by its proven efficacy, widespread use, and crucial role in treating ischemic strokes
- In 2023, the hospital pharmacies segment dominated the cerebral infarction treatment market, capturing a substantial revenue share of 63.6%
The leading players in the Cerebral Infarction Treatment market include:
- Amgen Inc.
- Pfizer Inc.
- Novartis AG
- Amneal Pharmaceuticals LLC
- Sanofi
- Abbott Laboratories
- Johnson & Johnson
- Bristol-Myers Squibb
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Cerebral Infarction Treatment Market Variables, Trends & Scope
Chapter 4. Cerebral Infarction Treatment Market: Treatment Estimates & Trend Analysis
Chapter 5. Cerebral Infarction Treatment Market: Drug Class Estimates & Trend Analysis
Chapter 6. Cerebral Infarction Treatment Market: Distribution Channel Estimates & Trend Analysis
Chapter 7. Cerebral Infarction Treatment Market: Regional Estimates & Trend Analysis by Treatment, Drug Class, and Distribution Channel
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players in the Cerebral Infarction Treatment market include:- Amgen Inc.
- Pfizer Inc.
- Novartis AG
- Amneal Pharmaceuticals LLC
- Sanofi
- Abbott Laboratories
- Johnson & Johnson
- Bristol-Myers Squibb
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 120 |
Published | September 2024 |
Forecast Period | 2023 - 2030 |
Estimated Market Value ( USD | $ 12.4 Billion |
Forecasted Market Value ( USD | $ 20.5 Billion |
Compound Annual Growth Rate | 7.3% |
Regions Covered | Global |
No. of Companies Mentioned | 9 |